Spyre Therapeutics’ Post

What makes someone with #ATTR #CM, NYHA class III, HF on diuretics, with NTproBNP 5k, do well over 4 years? Now NYHA I, same diuretics, no HF events, NTproBNP 3k. On tafamidis for 5 years, granted initially had worsening HF ~1 year then stabilized We are ok in predicting the extremes of prognosis in #ATTR #CM But we aren't anywhere near precise predictions for the majority in between. Therapies/clinical trials are complicating this further #Amyloidosis

News of the week: 12-month results for Phase 2 trial evaluating heat-therapy system for MGD, topline results from targeted photobiomodulation for treatment of progressive myopia, enrollment complete in Phase 3 trials to evaluate new wet AMD therapy, and more. Read all about it in EyeWorld Weekly

Polling Q5/5 concludes this incredible 10-day #tutorial journey! What are the 4L treatment choices for ER+/HER2-low mBC patients? Join Dr. Aditya Bardia, one last time, for his response video, analyzing data on #ADCs including the noteworthy DESTINY-Breast04 & TROPICS-02 trials.  A heartfelt thanks to all for your active participation and for following along the hypothetical case of Amber for these 10-days! Special appreciation to Dr. Bardia for his invaluable collaboration. Clinical Takeaways:  1. Elacestrant increases PFS vs. SOC in ESR1m patients, irrespective of PIK3CAm or HER2-low status 2. Hyperglycemiais a target side effect of the PIK3CAi and needs to be monitored closely. 3. T-DXd can be considered in HER2-low mBC post ≥1 line of ChT

February is declared as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month by Prevent Blindness. Take this month to learn more at Prevent Blindness AMD Low-Vision-Month. At Ocugen, we are developing OCU410, a potential curative therapy for dry AMD. For more information on the Phase 1/2 clinical trial of OCU410, contact clinical.request@ocugen.com. #dAMD #genetherapy #courageousinnovation

#MantleCellLymphoma consists of a spectrum of clinical subtypes.¹ However, diagnosing cases of cyclin D1-negative #MCL can be challenging.¹,² How do you approach the diagnosis and management of cyclin D1-negative MCL in your practice? #ASH23

Daxor’s CLIA-certified facility provides next day #BVA test results - requires no capital investment, easily integrates into workflow, approved for reimbursement with both public and private insurance. Discover more: https://lnkd.in/eftgyN7W #cardiology #criticalcare #heartfailure #nuclearmedicine

What is the safety and efficacy of allo-HSCT in patients with R/R T-ALL/LBL who achieved CR after CD7-directed CAR T-cell therapy? Find out more here https://loom.ly/zFYaC30 #ALLsm #leusm #MedEducation

Attending ACC 2024? Seeking conference coverage support in the cardiometabolic realm? CVrg is all set to analyze the latest data, especially in HF, DYS/ATH, and other CVM indications. Curious about our year-round conference plans? Reach out to Brooke Blackwelder for details into how CVrg can support your needs! Let's navigate the cardiometabolic landscape together! #ACC24 #Cardiometabolic #cardiovascular #pharmaCI #competitveintelligence #pipelinestrategy

The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/3w6d6oI Risk Info: https://bit.ly/44rllbl TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

We're excited to share that Venus Medtech's self-developed Transcatheter Pulmonary Valve Replacement (TPVR) system, VenusP-Valve, has successfully held its kick-off meeting at the University of Virginia School of Medicine (UVA) for the PROTEUS IDE clinical study. This marks another significant step forward since the product received IDE approval from the US FDA last year, marking the official commencement of the crucial clinical trial enrollment in the United States. The PROTEUS clinical study is a prospective, multi-center, non-randomized, interventional study for patients with moderate to severe pulmonary regurgitation accompanied by native Right Ventricular Outflow Tract (RVOT) dysfunction. The study will enroll 60 patients, and its data will support registration applications with both the US FDA and Japan's PMDA. Stay tuned for further updates! #QMportfolio #QMhealthcare #medtech #VenusP #clinicalstudy #VenusMedtech #PROTEUS #ClinicalTrials #VenusPValve